Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III are obtained from mice immunized with human tumors

Brockhaus, Manfred; Magnani, John L.; Herlyn, Meenhard; Błaszczyk, M; Steplewski, Zenon; Koprowski, Hilary; Ginsburg, Victor

doi:10.1016/0003-9861(82)90546-x

Cited by 114 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Methodsmentioning

confidence: 99%

“…Mouse monoclonal antibodies RlB19, S4-7, S3-13, and S17-25 were derived in our laboratory, as described, by immunizing mice with acute myeloblastic leukemia cells (18,19). WGHS-29-1 was generated in the laboratory of H. Koprowski and Z. Steplewski (Wistar Institute, Philadelphia) (20) by immunization with primary gastric adenocarcinoma and was characterized for its reactivity with hemopoietic cells by us.Antibodies S3-13, S4-7, R1B19, WGHS-29-1, and S17-25 (IgM isotype) all were found to be cytotoxic in the presence of complement. Antibodies WGHS-29-1, R1B19, and S4-7 react with carbohydrate moieties of glycolipids and glycoproteins (ref.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow.

Ferrero¹,

Broxmeyer²,

Pagliardi³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Two types of progenitor cells of the human granulocytic and monocytic lineages (CFU-GM) can be distinguished by using mouse monoclonal antibodies against human hemopoietic cells. Type 1 CFU-GM contribute all of the peripheral blood CFU-GM as well as a small fraction of bone marrow CFU-GM and express surface antigens recognized by "anti-lymphomonocytic" monoclonal antibodies S3-13 and S17-25 but not the antigens recognized by R1B19 and WGHS-29-1 (two monoclonal antibodies that react with all the cells of the granulocytic lineage). Type 2 CFU-GM are present only in the marrow and react with S3-13, RlB19, and WGHS-29-1. Partial reactivity with S17-25 was observed only in the complement-dependent cytotoxicity test. In vitro culture of type 1 CFU-GM in liquid medium in the presence of granulocyte-macrophage colony-stimulatory factor (GM-CSF) generates colony-forming cells that have the surface phenotype of type 2 CFU-GM. This finding supports the idea of two different stages of maturation of myelomonocytic progenitor cells represented by type 1 and type 2 CFU-GM.The early stages of myeloid differentiation from pluripotent stem cells to morphologically recognizable myeloblasts are not yet completely defined. The ability to grow granulocyte-macrophage progenitor cells (CFU-GM) in vitro (1-3) has provided information about both normal and abnormal progenitor cells (4). CFU-GM are considered to be cells committed to the generation of granulocytes and monocytes (5) and to represent an intermediate population between the pluripotent stem cells and morphologically recognizable myeloid cells (6). However, there is evidence to suggest the existence of CFU-GM subpopulations that differ in size (7-9), density (10), stage of cell cycle (8, 9), and responsiveness to different stimulators (7,11).Surface antigens of CFU-GM have also been studied by using polyclonal heteroantisera and monoclonal antibodies that recognize antigens related or unrelated to the HLA system (12)(13)(14)(15) Monoclonal Antibodies. Mouse monoclonal antibodies RlB19, S4-7, S3-13, and S17-25 were derived in our laboratory, as described, by immunizing mice with acute myeloblastic leukemia cells (18,19). WGHS-29-1 was generated in the laboratory of H. Koprowski and Z. Steplewski (Wistar Institute, Philadelphia) (20) by immunization with primary gastric adenocarcinoma and was characterized for its reactivity with hemopoietic cells by us.Antibodies S3-13, S4-7, R1B19, WGHS-29-1, and S17-25 (IgM isotype) all were found to be cytotoxic in the presence of complement. Antibodies WGHS-29-1, R1B19, and S4-7 react with carbohydrate moieties of glycolipids and glycoproteins (ref. 20; unpublished data). Antibody WGHS-29-1 has been shown to react specifically with the oligosaccharide fucopentaose III (20), the antigenic determinant also recognized by anti-SSEA-1 antibody (21). Antibody RIB19 immunoprecipitates glycoproteins of 145 and 105 kilodaltons, similar to those precipitated by antibody S4-7 (unpublished data). S3-13 immunoprecipitates a 29-kilodalton prot...

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow.

Ferrero¹,

Broxmeyer²,

Pagliardi³

et al. 1983

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…changes in the serum reactivity to these antibodies can reflect the extent of dis ease and the response of the patient to thera py, as has been previously demonstrated for the monoclonal antibody OC 125 [2], Several murine monoclonal antibodies directed to ward glycolipid antigenic determinants of gastrointestinal carcinoma cells have been developed, including the IgM monoclonal antibody GA 29-1 [3]. This antibody is di rected toward the carbohydrate moiety lacto-N-fucopentaose III (LNF III) [4].…”

Section: Introductionmentioning

confidence: 99%

“…Previously, it has been de scribed as both the Lc X determinant and as the stage-specific mouse embryonic antigen [6]. This antigenic determinant site has been reported to be present in various normal and malignant tissues and in the circulation of patients with gastrointestinal cancers [3,7,8].…”

Section: Introductionmentioning

confidence: 99%

“…This antibody is di rected toward the carbohydrate moiety lacto-N-fucopentaose III (LNF III) [4]. This epi tope consists of a sugar sequence first isolated from oligosaccharides contained in human milk [5] and later isolated from human ade nocarcinoma [3]. Previously, it has been de scribed as both the Lc X determinant and as the stage-specific mouse embryonic antigen [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lacto-N-Fucopentaose III Activity in the Serum of Patients with Ovarian Carcinoma

Cox¹,

Freedman

1986

Gynecol Obstet Invest

View full text Add to dashboard Cite

The expression of the lacto-N-fucopentaose III (LNF III) epitope by tumor cells of the gastrointestinal tract and ovary has been observed in tissue sections with the use of the murine monoclonal antibody GA 29–1. The presence of the LNF III epitope in the circulation of patients with colorectal cancer has also been reported. In this preliminary study, we describe the presence of LNF III activity in the serum of patients with adenocarcinoma of the ovary. Twelve of 18 (66%) patients with stage I-IV disease demonstrated high reactivity to the GA 29–1 monoclonal antibody. This serum reactivity was independent of disease stage and histologic cell type. In contrast, only 1 of 6 control patients demonstrated a false-positive level of reactivity to GA 29–1. These preliminary results suggest that LNF III warrants further study of its potential application as a serum tumor marker test in patients with adenocarcinoma of the ovary.

show abstract

Immunohistochemical studies of blood group substance h in colorectal tumors using a monoclonal antibody

Compton

Wyatt

Konugres

et al. 1987

Cancer

View full text Add to dashboard Cite

With the use of a murine monoclonal antibody with specificity for human blood group substance H, the distribution of this antigen on colorectal carcinomas and adenomatous polyps has been studied by immunohistochemistry. All of the 20 carcinomas studied were found to express H substance regardless of their location in the colon, their pathologic grade, or their clinical stage. Adenomas were variably positive for H substance, and expression of the antigen appeared to correlate with the degree of dysplasia seen on microscopic examination. Normal colonic mucosa, nonadenomatous polyps, and nonepithelial colonic neoplasms studied failed to express H substance. The results suggest that detection of H substance expression may be useful in the diagnosis of colonic malignancies and dysplastic premalignant lesions.

show abstract

Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III are obtained from mice immunized with human tumors

Cited by 114 publications

References 9 publications

Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow.

Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow.

Lacto-N-Fucopentaose III Activity in the Serum of Patients with Ovarian Carcinoma

Immunohistochemical studies of blood group substance h in colorectal tumors using a monoclonal antibody

Contact Info

Product

Resources

About